617PDA phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data. (23rd October 2018) - Satoh, T; Chen, L-T; Kang, Y-K; Chao, Y; Kato, K; Chung, H C; Chen, J-S; Muro, K; Kang, W K; Yoshikawa, T; Oh, S C; Tamura, T; et al.